News

In September 2018 the European Commission granted marketing authorization for NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast

AJOVY is a humanized monoclonal antibody (mAb) that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. AJOVY is the first and

The early-stage trial is assessing the safety and efficacy of the ipatasertib combination in patients with locally advanced or metastatic triple-negative breast cancer who previously did not receive

TUDORZA PRESSAIR is indicated for the maintenance treatment of patients with COPD. According to Kenneth Chapman, MD, Clinical Researcher, Krembil Research Institute, University Health Network, University of Toronto,

Boehringer Ingelheim, along with nanoPET Pharma, will use the MacroDel biologics-delivery platform to develop novel therapeutics. nanoPET Pharma is a former shareholder of ICD Therapeutics. nanoPET Pharma managing

The CHMP recommended approval of an expanded indication of REVLIMID as combination therapy with bortezomib and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple

As part of the global development and commercialization collaboration, AstraZeneca and Daiichi Sankyo will develop and commercialize trastuzumab deruxtecan (DS-8201), which is an antibody-drug conjugate (ADC) and potential

This is the first time that the FDA has approved a treatment for nr-axSpA. “Today’s approval of Cimzia fulfills an unmet need for patients suffering from non-radiographic axial

The investment will cover a new building dedicated to Merck biotech medicines destined for more than 150 countries, helping to meet increasing patient needs for flagship medicines such